ATE390917T1 - Prävention und behandlung von skeletterkrankungen mit ep2 subtyp selektiven prostaglandin e2 agonisten - Google Patents

Prävention und behandlung von skeletterkrankungen mit ep2 subtyp selektiven prostaglandin e2 agonisten

Info

Publication number
ATE390917T1
ATE390917T1 AT97911412T AT97911412T ATE390917T1 AT E390917 T1 ATE390917 T1 AT E390917T1 AT 97911412 T AT97911412 T AT 97911412T AT 97911412 T AT97911412 T AT 97911412T AT E390917 T1 ATE390917 T1 AT E390917T1
Authority
AT
Austria
Prior art keywords
agonists
prevention
treatment
subtype selective
selective prostaglandin
Prior art date
Application number
AT97911412T
Other languages
English (en)
Inventor
Kimberly Cameron
Hua KE
Bruce Lefker
Robert Rosati
David Thompson
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Application granted granted Critical
Publication of ATE390917T1 publication Critical patent/ATE390917T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
AT97911412T 1996-12-20 1997-11-27 Prävention und behandlung von skeletterkrankungen mit ep2 subtyp selektiven prostaglandin e2 agonisten ATE390917T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US3356996P 1996-12-20 1996-12-20

Publications (1)

Publication Number Publication Date
ATE390917T1 true ATE390917T1 (de) 2008-04-15

Family

ID=21871174

Family Applications (1)

Application Number Title Priority Date Filing Date
AT97911412T ATE390917T1 (de) 1996-12-20 1997-11-27 Prävention und behandlung von skeletterkrankungen mit ep2 subtyp selektiven prostaglandin e2 agonisten

Country Status (19)

Country Link
US (1) US6426359B1 (de)
EP (1) EP0951282B1 (de)
JP (2) JP2000507961A (de)
KR (1) KR100359557B1 (de)
AT (1) ATE390917T1 (de)
AU (1) AU4881697A (de)
CA (1) CA2275595C (de)
CY (1) CY2610B2 (de)
DE (1) DE69738613T2 (de)
DK (1) DK0951282T3 (de)
ES (1) ES2303341T3 (de)
HU (1) HUP0001836A3 (de)
IL (2) IL130333A0 (de)
MY (1) MY132818A (de)
NZ (1) NZ335770A (de)
PT (1) PT951282E (de)
TW (1) TW562677B (de)
WO (1) WO1998027976A1 (de)
ZA (1) ZA9711435B (de)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA59384C2 (uk) * 1996-12-20 2003-09-15 Пфайзер, Інк. Похідні сульфонамідів та амідів як агоністи простагландину, фармацевтична композиція та способи лікування на їх основі
ES2303341T3 (es) 1996-12-20 2008-08-01 Pfizer Inc. Prevencion y tratamiento de trastorno del esqueleto con agonistas de la prostaglandina e2 selectivos del subtipo de receptor ep2.
EP1000619A3 (de) * 1998-06-23 2002-07-24 Pfizer Products Inc. Verfahren zur Behandlung von Glaukoma
US6414006B1 (en) 1998-10-15 2002-07-02 Merck Frosst Canada & Co. Methods for inhibiting bone resorption
WO2000029614A1 (en) * 1998-11-12 2000-05-25 Gemini Genomics Ab. Human prostaglandin receptors and methods of use thereof
ATE281432T1 (de) 1999-03-05 2004-11-15 Univ Duke C-16 ungesätigte fp-selektive prostaglandin analoge
US6894175B1 (en) 1999-08-04 2005-05-17 The Procter & Gamble Company 2-Decarboxy-2-phosphinico prostaglandin derivatives and methods for their preparation and use
TWI247606B (en) * 1999-11-24 2006-01-21 Ono Pharmaceutical Co Treating agent for osteopenic diseases
RU2259830C2 (ru) * 1999-11-24 2005-09-10 Оно Фармасьютикал Ко., Лтд. Фармацевтическая композиция для лечения заболеваний, связанных с потерей костной массы
AP2001002357A0 (en) * 1999-12-22 2001-12-31 Pfizer Prod Inc EP4 receptor selective agonists in the treatment of osteoporosis.
US20010056060A1 (en) * 2000-02-07 2001-12-27 Cameron Kimberly O. Treatment of osteoporsis with EP2/EP4 receptor selective agonists
US20020037914A1 (en) 2000-03-31 2002-03-28 Delong Mitchell Anthony Compositions and methods for treating hair loss using C16-C20 aromatic tetrahydro prostaglandins
US20020013294A1 (en) 2000-03-31 2002-01-31 Delong Mitchell Anthony Cosmetic and pharmaceutical compositions and methods using 2-decarboxy-2-phosphinico derivatives
US20020172693A1 (en) 2000-03-31 2002-11-21 Delong Michell Anthony Compositions and methods for treating hair loss using non-naturally occurring prostaglandins
FR2812192B1 (fr) * 2000-07-28 2003-01-31 Oreal Utilisation d'antagonistes de recepteur des prostaglandines ep-3 comme agent cosmetique permettant d'attenuer, de diminuer ou d'arreter la chute des cheveux et des poils
FR2812190B1 (fr) * 2000-07-28 2003-01-31 Oreal Utilisation d'agonistes non prostanoiques des recepteurs des prostaglandines ep-2 et/ou ep-4 comme agent cosmetique permettant d'attenuer, de diminuer ou d'arreter la chute des cheveux et des poils
PL370914A1 (en) * 2001-11-30 2005-06-13 Pfizer Products Inc. Pharmaceutical compositions and methods for administering ep2 receptor selective agonists
WO2004073591A2 (en) * 2003-02-24 2004-09-02 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with g-protein coupled receptor prostaglandin e2 ep2 (prostaglandin e2 ep2)
CA2518193A1 (en) * 2003-03-04 2004-09-16 Pfizer Products Inc. Use of ep2 selective receptor agonists in medical treatment
EP2422814A1 (de) * 2003-07-25 2012-02-29 Ono Pharmaceutical Co., Ltd. Heilmittel für Knorpelerkrankungen
WO2005027931A1 (en) * 2003-09-19 2005-03-31 Pfizer Products Inc. Pharmaceutical compositions and methods comprising combinations of 2-alkylidene-19-nor-vitamin d derivatives and an ep2 or ep4 selective agonist
WO2005080367A1 (en) 2004-02-12 2005-09-01 Pharmagene Laboratories Limited Ep2 receptor agonists
BRPI0605926A2 (pt) 2005-01-14 2009-05-26 Allergan Inc ciclopentanos substituìdos ou ciclopentanonas como agentes terapêuticos
CA2618486A1 (en) 2005-08-09 2007-02-15 Asterand Uk Limited Ep2 receptor agonists
US7323591B2 (en) 2006-01-10 2008-01-29 Allergan, Inc. Substituted cyclopentanes or cyclopentanones as therapeutic agents
EP2220057A4 (de) * 2007-11-14 2011-10-12 Cayman Chem Co Prostaglandin-e1- und e2-analoga zur behandlung verschiedener medizinischer leiden
EP2291346A2 (de) 2008-05-15 2011-03-09 Allergan, Inc. Therapeutische substituierte cyclopentane

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4033996A (en) 1973-04-25 1977-07-05 Merck & Co., Inc. 8-Aza-9-oxo(and dioxo)-thia-11,12-secoprostaglandins
US4018892A (en) 1975-08-06 1977-04-19 Pfizer Inc. Bone deposition by 16-aryl-13,14-dihydro-PGE2 p-biphenyl esters
US4112236A (en) 1977-04-04 1978-09-05 Merck & Co., Inc. Interphenylene 8-aza-9-dioxothia-11,12-secoprostaglandins
AU615534B2 (en) 1988-04-19 1991-10-03 Teijin Limited 2-substituted-2-cyclopentenones
US5409911A (en) 1992-09-11 1995-04-25 Merck & Co., Inc. Prostaglandin analog for treating osteoporosis
US5605814A (en) 1993-08-31 1997-02-25 Merck Frosst Canada Inc. DNA encoding human prostaglandin receptor EP2
US5698598A (en) 1995-08-04 1997-12-16 Allergan EP2 -receptor agonists as agents for lowering intraocular pressure
ES2303341T3 (es) 1996-12-20 2008-08-01 Pfizer Inc. Prevencion y tratamiento de trastorno del esqueleto con agonistas de la prostaglandina e2 selectivos del subtipo de receptor ep2.
UA59384C2 (uk) 1996-12-20 2003-09-15 Пфайзер, Інк. Похідні сульфонамідів та амідів як агоністи простагландину, фармацевтична композиція та способи лікування на їх основі
NO317155B1 (no) 1997-02-04 2004-08-30 Ono Pharmaceutical Co <omega>-cykloalkyl-prostagladin-E<N>2</N>-derivater

Also Published As

Publication number Publication date
ES2303341T3 (es) 2008-08-01
MY132818A (en) 2007-10-31
TW562677B (en) 2003-11-21
AU4881697A (en) 1998-07-17
HUP0001836A3 (en) 2001-05-28
DE69738613T2 (de) 2009-04-30
JP2006290895A (ja) 2006-10-26
EP0951282B1 (de) 2008-04-02
EP0951282A1 (de) 1999-10-27
CY2610B2 (en) 2010-10-22
IL130333A (en) 2007-02-11
CA2275595A1 (en) 1998-07-02
NZ335770A (en) 2005-01-28
US6426359B1 (en) 2002-07-30
JP2000507961A (ja) 2000-06-27
HUP0001836A2 (hu) 2000-09-28
KR100359557B1 (ko) 2002-11-08
ZA9711435B (en) 1999-06-21
KR20000057680A (ko) 2000-09-25
IL130333A0 (en) 2000-06-01
DK0951282T3 (da) 2008-07-14
DE69738613D1 (de) 2008-05-15
PT951282E (pt) 2008-06-09
WO1998027976A1 (en) 1998-07-02
CA2275595C (en) 2003-08-05

Similar Documents

Publication Publication Date Title
ATE390917T1 (de) Prävention und behandlung von skeletterkrankungen mit ep2 subtyp selektiven prostaglandin e2 agonisten
MY129189A (en) Prostaglandin agonists and their use to treat bone disorders
TR200102021T2 (tr) TWEAK ve TWEAK reseptörü antagonistleri ve bunların imünolojik bozuklukların iyileştirilmesi için kullanımları
ES2168650T3 (es) Compuestos y metodos moduladores de receptores de androgenos.
ATE209047T1 (de) Epoxysteroide aldosteronantagonist und angiotensin ii rezeptor antagonist kombinationstherapie zur behandlung von congestivem herzversagen
YU7797A (sh) Kombinovana terapija za osteoporozu
HUP9700603A1 (hu) Gyógyászati készítmény véralvadási zavarok kezelésére
TR200000913T2 (tr) Tıbbi maddeler
NZ324500A (en) Humanized antibodies to human gp39, compositions containing and therapeutic use thereof
ATE299710T1 (de) Methoden zur behandlung von muskelerkrankungen und muskelstörungen
FR2786664B1 (fr) Procede de traitement de fruits et legumes utilisant l&#39;eugenol et/ou l&#39;isoeugenol et utilisation d&#39;une composition a base d&#39;eugenol et/ou d&#39;isoeugenol
ATE510552T1 (de) Verfahren zur herstellung von sekretierte verkurzte varianten des humanen thyrotropinrezeptors
BR9510499A (pt) Antagonistas de il-5 recombinantes úteis no tratamento de distúrbios mediados po il-5
ATE210447T1 (de) Verwendung von cck-b rezeptor antagonisten zur behandlung von schlafstörungen
ATE381533T1 (de) Pharmazeutisch wirksame verbindungen und methoden zu ihrer anwendung
DE69711078D1 (de) Topische verwendung von kappa-opioidrezeptoragonisten zur behandlung von augenschmerz
DE69110713D1 (de) 7-Oxabicycloheptan-imidazol-prostaglandin-Analoge, verwendbar bei der Behandlung von thrombotischen und vasospastischen Erkrankungen.
DE69638281D1 (de) Anti-Interleukin-9 Antikörper oder Anti-Interleukin-9 Rezeptor Antikörper zur Behandlung von bronchialem Hyperreaktionsvermögen
MX9101958A (es) Inhibidores de acat de urea de aminosulfonilo
DE69735417D1 (de) 2,5-dihydroxybenzylsulfonderivate zur behandlung von sexuellen störungen
TR200200278T2 (tr) Kalsilitik bileşimler
TR199901385T2 (xx) Piperidin t�revleri.
DE69829995D1 (de) Multivalente rekombinante antikörper zur behandlung von hrv infektionen
DE3378979D1 (en) 1-acyl-3-pyridylmethylguanidines and their use as antihypertensive agents
DK0956038T3 (da) Morfogen peptidinduceret regeneration af senseopfattelsesvæv

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0951282

Country of ref document: EP